Medidata Solutions Selected to Support U.S. Government Research on Drug Development Costs
HHS National Research Effort Will Rely on Medidata Databases to Improve Clinical Trial Process
The U.S. Department of Health and Human Services (HHS) and consulting firm Eastern Research Group, Inc . (ERG) have selected the comprehensive trial cost database products from Medidata Solutions (NASDAQ: MDSO) to drive research into improving the clinical trial process industry-wide. Through Medidata Grants Manager ® and Medidata CRO Contractor ® , HHS will have access to Medidata’s extensive proprietary databases containing information from over 275,000 negotiated clinical site grants and almost 9,000 outsourced R&D contracts.
In support of HHS’ goal of bringing health-related innovation to the public faster, ERG will analyze Medidata’s trial cost data to identify factors that delay or derail clinical studies. ERG will also assist HHS in assessing the economic benefit of implementing policies that encourage more streamlined clinical trials for the efficient delivery of safe and effective new therapies.
Medidata Grants Manager and Medidata CRO Contractor data solutions are widely used by pharmaceutical companies, contract research organizations (CROs) and academic researchers to identify prevailing rates for trial planning, budget development and grant negotiation. Uniquely, Medidata Grants Manager’s database, PICAS® , and CRO Contractor’s database, CROCAS® , contain hundreds of thousands of data elements derived from actual negotiated contracts, analyzable at any combination of therapeutic level, phase or geography, in easy-to-use computer-based analytic tools. With this breadth of globally accessible real-world information, these databases have become an industry standard for measuring trial cost trends.
The HHS and ERG research will be conducted over the next several months, with results expected by the end of this year.
- “Medidata’s PICAS and CROCAS databases are the perfect inputs to our research, providing the broadest, most comprehensive collection of real-world negotiated trial costs that can be disaggregated and examined,” said Aylin Sertkaya, vice president, ERG.
Over the past several years, clinical trial cost data from Medidata Grants Manager and CRO Contractor have been relied on not only by pharmaceutical, biotech and medical device companies, but also by government, academic and non-profit institute researchers analyzing the industry. Recent customers include the National Bureau of Economic Research , which is using the data to develop a trendable cost index for clinical trials; and Pharmaceutical Research and Manufacturers of America (PhRMA), the major trade group for the global pharmaceutical industry, who, along with economic consulting firm Analysis Group, Inc., is using the industry data to research the costs of post-approval clinical trials.
- “We are delighted to have HHS leveraging the Medidata platform in the pursuit of more efficient clinical trials, with the ultimate goal of getting effective therapies to the patients who need them,” said Glen de Vries, president, Medidata Solutions. “While our data products are used by a broad set of life sciences companies to efficiently plan and manage their trials on a daily basis, they are also increasingly a key input for the vital research driving innovative improvements on an industry-wide scale.”
Connect with Medidata:
- Read our blog, Geeks Talk Clinical
- Tweet this: Extensive trial cost benchmark data from @Medidata chosen by @HHSGov for research to reform No. clinical development http://bit.ly/NaygEK
- Follow us on Twitter: @Medidata
- Find us on LinkedIn
About U.S. Department of Health & Human Services (HHS)
HHS is the United States government’s principal agency for protecting the health of all Americans and providing essential human services, especially for those who are least able to help themselves. HHS represents almost a quarter of all federal outlays, and it administers more grant dollars than all other federal agencies combined.
About Eastern Research Group, Inc. (ERG)
ERG is a multidisciplinary professional services firm with a proven track record in delivering high-quality, technically sophisticated, and quick-response scientific, technical, and outreach support in the areas of policy and economic analysis, program assessment, evaluation studies, data collection and analysis, performance measurement, technical assistance, environmental and public health assessment, website and publication development. ERG’s clients include the U.S. Department of Health and Human Services (DHHS); Agency for Toxic Substances and Disease Registry (ATSDR) and the Food and Drug Administration (FDA); as well as numerous offices and divisions throughout the U.S. Environmental Protection Agency (EPA), the U.S. Department of Energy (DOE), and the U.S. Occupational Safety and Health Administration (OSHA).
About Medidata Solutions Worldwide
Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.
Contact:
Lois Paul and Partners
Susan McCarron, 617-986-5767
Susan_McCarron@lpp.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Completes Acquisition of Intelsat, Creating Global Multi-Orbit Connectivity Powerhouse17.7.2025 07:30:00 CEST | Press release
New leading multi-orbit space company with a network of 120 GEO+MEO satellites and access to LEO constellations enables SES to better serve its customers SES, a leading space solutions company, today announced the completion of its highly value accretive acquisition of Intelsat, creating a strengthened global satellite operator with an expanded fleet of 120 satellites across two orbits. The newly combined company will leverage its skilled teams with deep vertical expertise to deliver integrated multi-orbit, multi-band satellite and connectivity solutions to businesses and governments around the world, creating a stronger multi-orbit operator with ~60% of revenue in high-growth segments. With a world-class network including approximately 90 geostationary (GEO), nearly 30 medium earth orbit (MEO) satellites, strategic access to low earth orbit (LEO) satellites, and an extensive ground network, SES can now deliver connectivity solutions utilising complementary spectrum bands including C-,
Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss17.7.2025 07:00:00 CEST | Press release
Final data from a first-of-its-kind clinical trial confirm that the combination of Sculptra® and Restylane® Lyft™ or Contour™* delivers sustained improvement in facial aesthetic appearance for patients experiencing facial volume loss due to medication-driven weight loss1 Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months1 Galderma continues to lead the response to addressing the aesthetic concerns of patients experiencing medication-driven weight loss, leveraging its deep dermatological expertise and working closely with healthcare professionals to meet evolving patient needs Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptrato address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.1 T
Global New Material International: Driving a Green Future Through Innovation17.7.2025 04:41:00 CEST | Press release
As global economic integration accelerates, materials science—the foundation of modern industry—is undergoing a profound transformation. Global New Material International Holdings Limited (GNMI) stands at the forefront of this evolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716430383/en/ Colored Building-Integrated Photovoltaic modules developed by CQV, a subsidiary of GNMI. At the recent 2nd Sino-European Corporate ESG Best Practice Conference, GNMI was honored with the “Best Practice in Technological Innovation” award for its outstanding commitment to innovation and green development. The judging panel praised the company’s achievements, noting that “GNMI’s innovations have gained broad international recognition. With a clear strategy focused on green manufacturing and sustainability, the company offers viable solutions to reduce dependence on non-renewable resources while advancing eco-friendly production.” T
Andersen Consulting styrker sin platform med tilføjelsen af Baufest16.7.2025 20:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Baufest, et globalt firma inden for digitalt produktdesign og -udvikling. Med mere end 30 års erfaring og kontorer i hele Amerika og Europa er Baufest anerkendt for at kombinere banebrydende teknologi med en dybdegående forståelse af forretningsstrategi og brugeroplevelse. Firmaet tilbyder et omfattende udvalg af tjenester, der omfatter forretningsdesign, udvikling af digitale produkter, data og anvendt AI og cybersikkerhed. Baufest betjener virksomhedskunder på tværs af nøgleindustrier som bank og finans, detailhandel, energi og sundhedspleje med fokus på at skabe målbare forretningsresultater gennem smidig, skalerbar og etisk teknologipraksis. "Vores samarbejde med Andersen Consulting er et vigtigt skridt fremad for de tjenester, vi tilbyder," siger Ángel Pérez Puletti, administrerende direktør for Baufest. "Andersens fulde pakke af specialiserede tjenester bygger på Baufests
ProAmpac Releases 2025 Sustainability Impact Report: A Decade of Flexibility. A Future of Possibilities16.7.2025 18:54:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, announces the release of its 2025 Sustainability Impact Report. This year’s theme, A Decade of Flexibility. A Future of Possibilities. celebrates the company’s decade-long journey of sustainable innovation and sets the foundation for its forward-looking climate and packaging goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716418035/en/ ProAmpac's 2025 Sustainability Impact Report “As we celebrate ten years of growth and innovation, we remain focused on what lies ahead: accelerating circular packaging, lowering our carbon footprint, and creating shared value for our employees, customers, communities, and partners. Our journey is far from over, but with every step, our purpose becomes clearer, and our momentum stronger,” said Greg Tucker, founder, vice-chairman, and chief executive officer of ProAmpac. Key highlights from the 2025 Impact Report incl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom